Study of ART0380 in Patients With Biologically Selected Solid Tumors

PHASE2TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

November 15, 2024

Study Completion Date

May 27, 2025

Conditions
Advanced Solid TumorRecurrent Endometrial CancerMetastatic Cancer
Interventions
DRUG

ART0380

Randomized patients will orally receive ART0380.

Trial Locations (15)

10065

Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital - Oncology, New York

11042

Northwell Health R.J. Zuckerberg Cancer Center, Lake Success

14076

Centre Francois Baclesse - Service d'Oncologie médicale, Caen

15224

Western Pennsylvania Hospital, Pittsburgh

23007

Hospital Universitario De Jaén, Jaén

46009

Fundación Instituto Valenciano De Oncología, Valencia

49055

Institut de Cancérologie de l'Ouest, Angers

69310

Hopital Lyon Sud, Pierre-Bénite

73104

University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City

75014

Hopital Cochin Saint Vincent De Paul, Paris

86000

Centre Hospitalier Universitaire De Poitiers, Poitiers

90095-1781

University of California Los Angeles (UCLA), Los Angeles

60637-1447

The University of Chicago, Chicago

02215

Dana Farber Cancer Center, Boston

02905

Women and Infants Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Artios Pharma Ltd

INDUSTRY